US 12,221,490 B2
Antibodies against hEPCR
Tarik Regad, Nottingham (GB)
Assigned to NOTTINGHAM TRENT UNIVERSITY, Nottingham (GB)
Appl. No. 17/428,816
Filed by NOTTINGHAM TRENT UNIVERSITY, Nottingham (GB)
PCT Filed Feb. 3, 2020, PCT No. PCT/GB2020/050244
§ 371(c)(1), (2) Date Aug. 5, 2021,
PCT Pub. No. WO2020/161478, PCT Pub. Date Aug. 13, 2020.
Claims priority of application No. 1901640 (GB), filed on Feb. 6, 2019.
Prior Publication US 2022/0127374 A1, Apr. 28, 2022
Int. Cl. C07K 16/30 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/3069 (2013.01) [A61P 35/00 (2018.01); C07K 16/2869 (2013.01)] 12 Claims
 
1. An antibody or antigen binding fragment thereof that binds to human EPCR (hEPCR), wherein the antibody comprises a light chain variable region and a heavy chain variable region, wherein the heavy chain variable region comprises:
(a) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 9;
(b) a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 10; and
(c) a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 11;
and wherein the light chain variable region comprises:
(a) a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 12;
(b) a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 13; and
(c) a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 14.